TY - JOUR T1 - Serum Creatinine and Prostate Cancer Risk in a Prospective Study JF - Cancer Epidemiology Biomarkers &amp; Prevention JO - Cancer Epidemiol Biomarkers Prev SP - 2643 LP - 2649 DO - 10.1158/1055-9965.EPI-09-0322 VL - 18 IS - 10 AU - Weinstein, Stephanie J. AU - Mackrain, Katrina AU - Stolzenberg-Solomon, Rachael Z. AU - Selhub, Jacob AU - Virtamo, Jarmo AU - Albanes, Demetrius Y1 - 2009/10/01 UR - http://cebp.aacrjournals.org/content/18/10/2643.abstract N2 - Background: Several studies have examined serum creatinine as a marker for prostate cancer stage, recurrence, and prognosis. We evaluated whether serum creatinine concentration was associated with risk of developing prostate cancer in a prospective cohort of male smokers.Methods: A nested case-control study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study of 50- to 69-year-old Finnish men was conducted. Two controls (n = 464) were matched to each case (n = 232) on study center, intervention group, date of baseline blood draw (±45 days), and age (±5 years). Conditional logistic regression was used to calculate odds ratios and 95% confidence intervals. All P values were two-sided.Results: Cases had significantly higher prediagnostic serum creatinine concentrations compared with controls (medians of 1.13 versus 1.10 mg/dL, respectively; P = 0.004). Serum creatinine was associated with a significantly greater risk of prostate cancer (multivariate odds ratio, 2.23; 95% confidence interval, 1.33-3.75 for highest versus lowest quartile), with a significant trend (P trend = 0.0008). Exclusion of subjects with a reported history of diabetes, benign prostatic hyperplasia, or hypertension, or whose cancer was diagnosed within the first 5 years of follow-up, did not alter the association. Risk did not differ by disease stage or time from blood draw to diagnosis.Conclusion: Prospectively measured serum creatinine, within normal ranges, is positively related to prostate cancer risk. Future research should reexamine the association in other populations, including any interrelationship with serum prostate-specific antigen. (Cancer Epidemiol Biomarkers Prev 2009;18(10):2643–9) ER -